BioSpace News Archive

Apellis is submitting additional 24-month efficacy data to supplement the NDA for its intravitreal candidate pegcetacoplan for GA secondary to AMD.

Some executives might book a massage or practice meditation to deal with their stress. Others have a different way to let off steam–spending time with their pets.

Sanofi and AstraZeneca won European approval for the first preventative RSV treatment for a broad population of newborns and infants.

The FDA is gearing up for deadlines and PDUFA dates in mid-November with Seagen, Provention, Clarus and Tolmar, and Ligand and Travere.

Arcus Biosciences and its collaboration partner Gilead Sciences announced during Arcus’ third-quarter report that the company had modified its ARC-10 Phase III trial.

Galapagos’ new “forward faster” strategy will see the departure of the company’s fibrosis and kidney disease programs and 200 staff members.

In spite of positive Phase IIb results from a thrombosis prevention trial, Ionis is back on the market for a new partner after Bayer returned the rights to the drug to Ionis.

BioAge Labs, PTC Therapeutics, Biogen and others highlighted novel mechanisms targeting newer pathways in neurodegenerative diseases at the recent Discovery on Target meeting.

Gelesis Holdings Inc. noted that the Company received a notification letter from the New York Stock Exchange advising that because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual.

Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that it is presenting at BioFuture™ 2022, which will take place at Lotte New York Palace, New York city, and providing an on-demand company presentation.